Risankizumab (Skyrizi®) is now FDA-approved (May, 2019) for the treatment of moderate to severe plaque psoriasis in adult patients who are eligible for systemic medication or phototherapy.
Risankizumab is a humanized monoclonal IgG1 antibody antagonist of IL-23, a cytokine mediator of chronic inflammation). By binding the p19 subunit of IL-23, it prevents IL-23 receptor binding and thereby inhibits a pro-inflammatory response. It is a SC-injected medication, dosed at 150 mg, and given at weeks 0 and 4 and subsequently, every 12 weeks.
ليست هناك تعليقات:
إرسال تعليق